Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs Post author:Sam Post published:January 25, 2018 Post category:BioPharma The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace You Might Also Like Merrimack Announces Expansion Of Senior Management Team With Appointment Of As Chief Medical Officer And As Head Of Human Resources June 7, 2017 MilliporeSigma Opens China's First BioReliance End-to-End Biodevelopment Center In Shanghai September 21, 2017 Anavex Issued New U.S. Patent For Composition Of Matter Covering ANAVEX 2-73 September 4, 2017
Merrimack Announces Expansion Of Senior Management Team With Appointment Of As Chief Medical Officer And As Head Of Human Resources June 7, 2017
MilliporeSigma Opens China's First BioReliance End-to-End Biodevelopment Center In Shanghai September 21, 2017
